RYTM: Rhythm Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (RYTM) is scaling its commercial reach by outsourcing the production of orphan drugs to external contractors. The development of new obesity medications is accelerating through AI, although trials still require medical supervision. An analysis of the company's short-term debt shows that the metric has settled at 0.01. High sales margins are maintained through strict oversight of specialized distributors within the supply chain.

RYTM (Rhythm Pharma) Company Short-Term Debts history from 07/04/2022 to 10/29/2026

RYTM (Rhythm Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Rhythm Pharmaceuticals, Inc.|RYTM - Fair Value Consensus
- market capitalization information:
Market Value Rhythm Pharmaceuticals, Inc.|RYTM - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Rhythm Pharmaceuticals|RYTM - Book Capitalization|Market Cap to Net Assets Ratio rhythmtx.com|RYTM - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Rhythm Pharmaceuticals|RYTM - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rhythm Pharmaceuticals|RYTM - Company Cumulative Debt|Debt to Book Value Rhythm Pharmaceuticals, Inc.|RYTM - Amount of Long-Term Liabilities|Company Short-Term Debts Rhythm Pharmaceuticals|Quick Ratio rhythmtx.com
- net income and valuation multiples indicators:
RYTM - Company Net Income
Basic company analysis:Rhythm Pharmaceuticals, Inc. - RYTM
Mass-produced product of Rhythm Corp

Efficiently scaling the production of peptide drugs through the validated capacities of CMO partners requires precise liquidity management. By analyzing the short-term debt portfolio, an investor assesses obligations maturing within one year, which reflects the current funding strategy for the operational cycles of Rhythm Pharmaceuticals (RYTM). The trend of this metric allows for the determination of the balance between financial stability and the aggressiveness of investments in expanding production lines.

Who Rhythm Pharmaceuticals competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Akero Corp|MTSR (Metsera Inc) - Company Short-Term Debts|Company Short-Term Debts moonlaketx.com|Company Current Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Soleno SLNO|FOLD - Company Current Liabilities|89bio, Inc. - Company Short-Term Debts|Short-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debt Lipocine Inc. LPCN|Company Short-Term Loans and Borrowings MTNB|Spruce Biosciences - Company Short-Term Debts|Company Short-Term Loans and Borrowings GLTO (Galecto Inc)|CTCX (Carmell Corp) - Company Current Liabilities|Short-Term Debt Lumos Therapeutics (LUMO)|Company Current Liabilities ONVO|RDUS (radiuspharm.com) - Amount of Current Liabilities